NCT06239272: NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 139 planned
- Started
- 27 Mar 2024
- Primary completion
- Jun 2034
- Arms
- Intermediate-Risk Subset A (participants with low grade tumors):, Intermediate-Risk Subset B (participants with high-grade tumors between 5 and 10 cm in size, Intermediate-Risk Subset C (participants with high-grade tumors > 10 cm):
- Results
- None posted
- 2 Feb 2024: Trial registered
- 27 Mar 2024: Trial started